BioXcel Therapeutics, Inc. (BTAI)

NASDAQ: BTAI · IEX Real-Time Price · USD
-1.00 (-5.28%)
At close: May 31, 2023, 4:00 PM
-0.33 (-1.84%)
After-hours: May 31, 2023, 6:36 PM EDT

Company Description

BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology.

The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices.

Its commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

The company also continues to conduct clinical trials evaluating BXCL501 for the treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia.

In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally administered, systemic innate immunity activator for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors.

The company was incorporated in 2017 and is headquartered in New Haven, Connecticut.

BioXcel Therapeutics, Inc.
BioXcel Therapeutics logo
Country United States
Founded 2017
IPO Date Mar 8, 2018
Industry Biotechnology
Sector Healthcare
Employees 183
CEO Dr. Vimal D. Mehta Ph.D.

Contact Details

555 Long Wharf Drive
New Haven, Connecticut 06511
United States
Phone 203-643-8060

Stock Details

Ticker Symbol BTAI
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001720893
CUSIP Number 09075P105
ISIN Number US09075P1057
Employer ID 82-1386754
SIC Code 2834

Key Executives

Name Position
Dr. Vimal D. Mehta Ph.D. Founder, Chief Executive Officer, President, and Director
Dr. Frank D. Yocca Ph.D. Senior Vice President and Chief Scientific Officer
Javier Rodriguez Senior Vice President, Chief Legal Officer and Corporate Secretary
Dr. Krishnan Nandabalan Ph.D. Chief Digital Officer ?& Director
Richard I. Steinhart MBA Senior Vice President and Chief Financial Officer
Mary Coleman Vice President of Investment Relations
Dr. Iris Francesconi Ph.D. Senior Vice President of Marketing, Market Research and Commercial Assessments
Dr. Vincent J. O'Neill M.D., B.Sc., M.R.C.P. Senior Vice President and Chief Medical Officer
Dr. Cedric Burg Vice President and Head of Global Clinical Operations and Project Management
Dr. Chetan D. Lathia Ph.D. Senior Vice President and Head of Translational Medicine, Clinical Pharmacology and Regulatory Affairs

Latest SEC Filings

Date Type Title
May 22, 2023 144 Filing
May 17, 2023 DEF 14A Other definitive proxy statements
May 16, 2023 144/A Filing
May 15, 2023 144 Filing
May 15, 2023 144 Filing
May 9, 2023 10-Q Quarterly Report
May 8, 2023 8-K Current Report
May 1, 2023 10-K/A [Amend] Annual report
Apr 20, 2023 8-K Current Report
Apr 4, 2023 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals